GlassScriptPhysician profile
Antoinette M Moran
NPI 1780618249
$62,949.86
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $9,489 · 2021: $300 · 2022: $6,490.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $52,518.82 | 2019-2022 | |
| Novo Nordisk As | $6,718.80 | 2019-2025 | |
| Dompe US, INC. | $3,300.00 | 2020-2021 | |
| Novo Nordisk INC | $248.75 | 2019 | |
| Medtronic, INC. | $87.28 | 2022 | |
| Medtronic Minimed, INC. | $63.55 | 2019 | |
| Mannkind Corporation | $12.66 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$22,660.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoinette Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.